Validating survivin as a cancer therapeutic target
Top Cited Papers
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 3 (1) , 46-54
- https://doi.org/10.1038/nrc968
Abstract
Acquisition of the ability to evade cellular suicide, or apoptosis, is one of the master switches that contributes to cellular transformation and, ultimately, to invasive cancer. Much has been learned about the molecular organization of apoptotic pathways and their regulators, but the identification and validation of translational targets for apoptosis-based cancer therapy has posed a great challenge. Survivin is an attractive candidate for cancer therapy, so what is its potential applicability in the clinic?Keywords
This publication has 107 references indexed in Scilit:
- IAP proteins: blocking the road to death's doorNature Reviews Molecular Cell Biology, 2002
- CRM1-Mediated Nuclear Export Determines the Cytoplasmic Localization of the Antiapoptotic Protein SurvivinExperimental Cell Research, 2002
- LATS1 tumor suppressor regulates G2/M transition and apoptosisOncogene, 2002
- Ubiquitin Protein Ligase Activity of IAPs and Their Degradation in Proteasomes in Response to Apoptotic StimuliScience, 2000
- Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell deathOncogene, 2000
- Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin PathwayJournal of Biological Chemistry, 2000
- High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastomaOncogene, 2000
- Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human MelanomaJournal of Investigative Dermatology, 1999
- Marked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial CellsBiochemical and Biophysical Research Communications, 1999
- Construction by gene targeting in human cells of a ‘conditional’ CDC2 mutant that rereplicates its DNANature Genetics, 1997